Hepatorenal Syndrome Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hepatorenal Syndrome Epidemiology Forecast Report Coverage

Expert Market Research's “Hepatorenal Syndrome Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hepatorenal syndrome (HRS). It projects the future incidence and prevalence rates of hepatorenal syndrome cases across various populations. The study covers age, gender, and type as major determinants of the hepatorenal syndrome population. The report highlights patterns in the prevalence of hepatorenal syndrome over time and projects future trends based on multiple variables.

Hepatorenal Syndrome Understanding: Disease Overview

Hepatorenal syndrome is a severe complication of advanced liver disease characterized by functional renal failure in the absence of intrinsic kidney pathology. It occurs due to profound circulatory dysfunction, including splanchnic vasodilation and renal vasoconstriction, leading to reduced renal perfusion. HRS is commonly associated with cirrhosis and ascites and is classified into acute and chronic forms based on progression. The condition carries poor prognosis, particularly in rapidly progressing cases. Diagnosis is clinical, requiring exclusion of other causes of renal impairment in patients with advanced liver disease.

Hepatorenal Syndrome Epidemiology Perspective

The hepatorenal syndrome epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hepatorenal syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatorenal syndrome and their trends. The hepatorenal syndrome detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Indika R. Ranasinghe, et al., 2023, globally, approximately 4% of patients with decompensated liver disease develop hepatorenal syndrome, primarily linked to portal hypertension caused by alcoholic hepatitis, cirrhosis, or metastatic liver involvement.
• As per Nazli Begum Ozturk, et al., 2023, among hospitalized cirrhotic patients with acute kidney injury, HRS accounts for 15-20% of cases, emphasizing its significant role in renal complications associated with advanced liver disease management worldwide.
• According to Jagmeet Singh, et al., 2021, the mean age of patients hospitalized with HRS ranged from 57.4 to 59.0 years, indicating that HRS most commonly affects middle‑aged to older adults with advanced liver disease.
• As per Akshata Borle et al. (2024), Hepatorenal Syndrome shows a strong male predominance, with 76% of patients identified as male. The study also reported 25% of cases in individuals aged 18–30 years, indicating notable occurrence among younger adults.

Read more about this report - Request a Free Sample

Country-wise Hepatorenal Syndrome Epidemiology Segment

The hepatorenal syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Hepatorenal syndrome represents a significant complication among patients with advanced liver disease across multiple countries. According to Syed Faisal Ali et al. (2026), the United States reported 118,894 HRS-related deaths from 1999 to 2024, with age-adjusted mortality declining from 2.43 to 2.12 per 100,000. Similarly, as per Kazuya Okushin, et al., 2023, Japanese inpatient data show a mean patient age of 67.3 years, with 65.4% male, underscoring substantial clinical burden. These observations highlight the importance of continued monitoring and early intervention across diverse populations.

Hepatorenal Syndrome: Treatment Overview

Hepatorenal syndrome treatment focuses on improving renal perfusion and managing underlying liver dysfunction. Vasoconstrictor therapy, including terlipressin in combination with albumin, is the standard medical approach to counteract circulatory abnormalities. Alternative agents such as norepinephrine may be used in critical care settings. Liver transplantation remains the definitive treatment, offering the best long-term survival outcomes. Supportive measures include management of precipitating factors, such as infections, and careful fluid balance. Emerging therapies are exploring novel vasoconstrictors and combination strategies to improve response rates and delay disease progression.

Key Questions Answered

• What are the key findings of hepatorenal syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with hepatorenal syndrome across the 8 major markets during the forecast period?
• What was the country-wise hepatorenal syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of hepatorenal syndrome during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hepatorenal syndrome during the forecast period of 2026-2035?
• What are the currently available treatments for hepatorenal syndrome (HRS)?
• What are the disease risks, signs, symptoms, and unmet needs of hepatorenal syndrome (HRS)?

Scope of the Hepatorenal Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hepatorenal syndrome based on several factors.
• Hepatorenal Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hepatorenal syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Chronic Kidney Disease Drug Pipeline Analysis

Chronic Kidney Disease Epidemiology

Acute Renal Failure/Acute Kidney Injury Epidemiology